Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.267 | uM | 12523.17 | 0.9889 | 0.9753 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 1.33 | uM | 12523.17 | 0.8233 | 0.6110 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 6.67 | uM | 12523.17 | 0.3804 | -0.3176 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Bosutinib | Src | nRTK | 33.3 | uM | 12523.17 | 0.3645 | -0.3492 | 0.8990 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 12239.145 | 0.9511 | 0.9535 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 12239.145 | 0.9405 | 0.9434 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 12239.145 | 0.9772 | 0.9785 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 12239.145 | 0.9649 | 0.9668 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 12239.145 | 0.9946 | 0.9949 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 12239.145 | 0.8137 | 0.8158 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 12239.145 | 0.3972 | 0.2978 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 12239.145 | 0.1131 | -0.2794 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 12239.145 | 0.3229 | 0.1778 | 2.1348 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 11849.145 | 0.8843 | 0.8451 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 11849.145 | 0.9806 | 0.9745 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 11849.145 | 0.9279 | 0.9042 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 11849.145 | 0.9013 | 0.8683 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 11849.145 | 0.9957 | 0.9944 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 11849.145 | 0.7842 | 0.7054 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 11849.145 | 0.3439 | -0.0067 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 11849.145 | 0.2034 | -0.2959 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 11849.145 | 0.1816 | -0.3463 | 1.5253 | |
| HCC1954 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 11055.145 | 0.9568 | 0.9505 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 11055.145 | 1.0042 | 1.0048 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 11055.145 | 0.9663 | 0.9614 | 1.7616 |